Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002558 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT00002558: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00002558 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002558, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support. PURPOSE: The purpose of this study is to determine the effects of an intensive sequence of chemotherapy drugs in patients with metastatic germ cell cancer. All of these chemotherapy drugs are known to be active in this disease.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG etoposide
- DRUG ifosfamide
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 1994-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002558
The ClinicalTrials.gov registry entry for NCT00002558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00002558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002558 about?
NCT00002558 is a clinical study titled "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy...
What is the current status of trial NCT00002558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 1994-01. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00002558?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), etoposide (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002558?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.